Naris Nilubol, M.D., F.A.C.S.
- Center for Cancer Research
- National Cancer Institute
- Building 10 - Room 45952
- Bethesda, MD 20892
Dr. Nilubol is a surgeon-scientist specialized in endocrine oncology surgery and clinical research involving thyroid, parathyroid, adrenal, and neuroendocrine tumors. His laboratory research focus includes the identification of novel targeted therapeutics in endocrine cancers and novel cancer drug delivery methods by targeting tumor microenvironment.
Areas of Expertise
1) endocrine surgery, 2) novel therapeutics in endocrine cancers, 3) cancer drug delivery,
4) neuroendocrine tumors, 5) thyroid cancer, 6) adrenal tumors
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Dr. Nilubol is the Principle Investigator of the protocol that comprehensively analyze molecular alterations in endocrine cancers that lead to tumor progression and metastasis. He will be the Principle Investigator that studies the von Hippel-Lindau disease (VHL)-associated pancreatic neuroendocrine tumors that aim to understand the molecular mechanisms involved in early metastasis by studying metabolomics and exosomes
Dr. Nilubol’s research program focuses on the identification of novel targeted therapeutics in endocrine cancers such as adrenocortical cancer and aggressive variants of thyroid cancers. Patients with these rare and aggressive cancers do not have treatment options with durable response. Dr. Nilubol collaborates with a number of NIH intramural investigators and uses the quantitative high-throughput drug screening method to identify candidate compounds from several pharmaceutical libraries containing approved drugs and natural compounds. Candidate compounds are being investigated in preclinical studies with the goal to translate the effective combinations of drugs to clinical trials in patients with advanced endocrine cancers. However, most of newly-discovered drugs do not show anti-tumor efficacy because there are many characteristics solid cancers that prohibit an effective drug delivery. Thus, Dr. Nilubol’s research focuses on targeting tumor microenvironment to reduce interstitial fluid pressure and increase drug delivery. To accomplish this goal, he utilizes gold nanomedicine carrying vascular disrupting agent (tumor necrosis factor alpha) specifically targeting tumor cells and its blood supply in collaborating with extramural investigators. The current research aim is to understand how TNF-α works on tumor microenvironment and how to induce the such response in tumors refractory to TNF-α. The nanomedicine carrying TNF-α is being evaluated for a clinical grade production for a phase II clinical trial in patients with advanced endocrine cancers.
Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors
Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response
High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy
Naris Nilubol, M.D., F.A.C.S.
Dr. Nilubol graduated from Chulalongkorn University Medical Center, Bangkok, Thailand with honors. He completed a surgery research fellowship followed by a general surgery training in 2005 at The Mount Sinai Hospital, New York, NY. Following surgery residency, Dr. Nilubol completed the Endocrine Oncology Surgery fellowship at Rush University Medical Center, Chicago, IL. Dr. Nilubol was on faculty at Mount Sinai Hospital, NY, before being recruited to NCI. In 2011, Dr. Nilubol received the Paul LoGerfo Research Award from the American Association of Endocrine Surgeons for the project involving the identification of novel treatments in adrenocortical cancer. There are over 100 peer-reviewed publications and several book chapters that Dr. Nilubol has authored.
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.
Learn more about CCR research advances, new discoveries and more on our news section.